Hepatitis C infection has affected 189 million people globally and more than 4 million in the
US. Owing to remarkable advances in the therapeutic sphere, essentially all infected …

Background Point-of-care testing (POCT) using rapid diagnostic tests for infectious disease
can potentially guide appropriate use of antimicrobials, reduce antimicrobial resistance, and …

Abstract Background In Germany, risk of hepatitis C virus (HCV) infection is highest among
people who inject drugs (PWID). New injectors (NI) are particularly vulnerable for HCV …

Summary Background The World Health Organization seeks to eliminate viral hepatitis as a
public health threat by 2030. This review and meta-analysis aims to evaluate the …

Background Point-of-care tests are characterised through the ability of conducting them near
the patient's side without the necessity of a laboratory. They can be applied in different …

Background Pharmacists are among the most accessible healthcare providers in the United
States and uniquely positioned to provide harm reduction services. The availability of …

Objectives To describe the first community pharmacy–based hepatitis C antibody (HCV-Ab)
point-of-care (POC) screening program and its outcomes in California. Setting Community …

Objective To describe the design and implementation of a pharmacist-led hepatitis C virus
(HCV) screening and education program in a community pharmacy with a protocol for …

Significant steps must be taken to reduce the global incidence and prevalence of hepatitis C
virus (HCV) and mortality from HCV infection to achieve the WHO goal of eliminating viral …

Hepatitis C direct-acting antivirals (DAAs) have an efficacy of 95% or greater, with
pangenotypic options. Many regions in Canada have recently abolished the need to …